China health care companies received a significant reprieve in terms of geopolitical risks when the US Senate declined to ...

Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...

Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense of RMB330 million. Major operating and financing activities generated RMB320 million cash inflows ...

In a trailblazing fusion of immunology and ingenuity, a team of Chinese researchers ... ovarian and lung – achieved halted tumour growth or shrinkage, with one cervical cancer patient declared ...

Chinese firms can accelerate clinical trials and bring their drugs to market faster with more supportive policies, ...

Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for ...

Jacobio Pharmaceuticals Group Co., Ltd. ( ($HK:1167) ) has issued an announcement. Jacobio Pharmaceuticals has announced significant progress in ...

Kelun-Biotech wins first global regulatory approval - in China - for a TROP2-directed antibody-drug conjugate (ADC) in lung cancer.

Holi 2025: The doctor explained that the primary concern of lung cancer from cannabis arises from being smoked, and not consumed orally. Holi 2025: Holi is almost here and many have already ...

Lung cancer arises in tissues of the lung, usually in the cells lining air passages. The two main types are small-cell lung cancer and non-small-cell lung cancer, according to the shape of cells ...